PTC Therapeutics, Inc.
NASDAQ:PTCTBiotechnology
+$0.60 today
- Market cap
- $5.03B
- Beta
- 0.55
- P/E (TTM)
- -35.0
- EPS (TTM)
- -$2.26
Volume 0.64M
Average 1.27M
PTCT EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
PTC Therapeutics, Inc.NASDAQ: PTCT
EPS (Basic) · Q2 FY2026 · quarter ended Jun 2026
EPS (Basic) turns positive
Q2 FY2026 EPS (Basic) was $1.01, compared with -$0.83 a year earlier. Trailing-twelve-month EPS (Basic) was -$0.49.
Context
- EPS (Basic) increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 7 analysts of $0.53 (-93.9%) for the fiscal year ending Dec 2026, a slowdown from the +281.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $1.01+3466.7% QoQ
- Last fiscal yearDec 2025
- $8.58+281.4% YoY
- LTMJun 2026
- -$0.49-106.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +221.7% | -28.3% | -250.0 pp |
| 1 year | +281.4% | -93.9% | -375.3 pp |
| 3-year CAGR | — | -20.1% | — |
| 5-year CAGR | -8.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- 8.58 USD
- Year-over-year change
- +281.4%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.58 | +281.4% |
| FY2024 | 2024-12-31 | (4.73) | +43.5% |
| FY2023 | 2023-12-31 | (8.37) | -7.4% |
| FY2022 | 2022-12-31 | (7.79) | -4.8% |
| FY2021 | 2021-12-31 | (7.43) | — |
EPS (Basic) vs competitors
How PTCT compares with its peers on the latest reported figures
- PTCT's LTM Jun 2026 EPS (Basic) of -$0.49 is the 4th highest of the 11 companies compared; the peer median is -$2.14.
- Its year-over-year change of -106.1% is the 10th highest of 11, against a peer median of +4.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $8.27 | +62.2% | — | |
| LTM Mar 2026 | $0.62 | +124.5% | — | |
| LTM Sep 2026 | -$0.09 | -103.3% | +33.8% | |
| LTM Jun 2026 | -$0.49 | -106.1% | — | |
| LTM Mar 2026 | -$1.06 | -27.7% | — | |
| LTM Mar 2026 | -$1.95 | +30.1% | — | |
| LTM Mar 2026 | -$2.32 | -63.4% | — | |
| LTM Sep 2026 | -$3.32 | -106.2% | — | |
| LTM Jun 2026 | -$3.33 | +13.7% | — | |
| LTM Jun 2026 | -$3.58 | +12.5% | — | |
| LTM Mar 2026 | -$6.11 | -3.9% | — | |
| Peer median (excluding PTCT) | -$2.14 | +4.3% | +33.8% | |
Competitors are the stored peer set for PTCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 538.59M | 698.8M | 937.82M | 806.78M | 1.73B |
| Cost of Revenue | 32.33M | 44.68M | 65.49M | 57.4M | 71.76M |
| Gross Profit | 506.27M | 654.12M | 872.34M | 749.38M | 1.66B |
| Gross Margin | 94.0% | 93.6% | 93.0% | 92.9% | 95.9% |
| Research & Development | 540.68M | 651.5M | 666.56M | 534.48M | 455.25M |
| Selling, General & Admin | 285.77M | 326M | 332.54M | 300.91M | 347.14M |
| Operating Expenses | 880.71M | 1.1B | 1.31B | 1.05B | 802.39M |
| Depreciation & Amortization | 64.13M | 128.84M | 236.59M | 75.66M | 38.82M |
| EBITDA | (368.18M) | (367.78M) | (330.34M) | (120.46M) | 887.66M |
| EBITDA Margin | -68.4% | -52.6% | -35.2% | -14.9% | 51.3% |
| Operating Income | (374.44M) | (447.41M) | (439.5M) | (302.57M) | 856.51M |
| Operating Margin | -69.5% | -64.0% | -46.9% | -37.5% | 49.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 86.02M | 90.87M | 129.18M | 166.99M | 152.23M |
| Other Income / Expenses | (143.9M) | (140.08M) | (256.61M) | (60.55M) | (159.89M) |
| Income Before Tax | (518.34M) | (587.49M) | (696.11M) | (363.12M) | 696.62M |
| Pre-Tax Margin | -96.2% | -84.1% | -74.2% | -45.0% | 40.3% |
| Income Tax Expense | 5.56M | (28.47M) | (69.51M) | 176K | 13.98M |
| Net Income | (523.9M) | (559.02M) | (626.6M) | (363.3M) | 682.64M |
| Net Margin | -97.3% | -80.0% | -66.8% | -45.0% | 39.4% |
| EPS (Basic) | (7.43) | (7.79) | (8.37) | (4.73) | 8.58 |
| EPS (Diluted) | (7.43) | (7.79) | (8.37) | (4.73) | 7.78 |
| Weighted Avg Shares | 70.47M | 71.73M | 74.84M | 76.85M | 79.53M |
| Weighted Avg Shares (Diluted) | 70.47M | 71.73M | 74.84M | 76.85M | 88.31M |
PTC Therapeutics, Inc.
NASDAQ:PTCT
Intrinsic Alpha fair value
Locked
Current Price
$60.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.